#United States #Chicago #Clinical Trials #Blood Cancer United #Beat AML

Blood Cancer United Reports Landmark Findings at 2026 ASCO and EHA

On May 28, 2026, Blood Cancer United announced that they will showcase over 50 research abstracts at two major medical conferences: the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and the European Hematology Association (EHA) Congress in Stockholm. This milestone marks a significant contribution to the ongoing dialogue about blood cancer treatment, patient experiences, and access challenges in healthcare.

Breakthroughs in Research

Lore Gruenbaum, Ph.D., the Chief Scientific Officer of Blood Cancer United, expressed excitement about the wealth of data and insights generated by funded research. These findings not only highlight potential new therapies but also address critical barriers faced by patients living with blood cancer. Gruenbaum emphasized the dual aspects of these presentations: advancing scientific knowledge and offering tangible lessons for clinical practices.

The research spans a variety of topics, from innovative treatment strategies to understanding the real-world cost barriers patients encounter when seeking care. Significant contributions will come from the Therapy Acceleration Program (TAP), with updates from fifteen current and former partners involved in clinical trials aimed at enhancing the quality of life for patients and their families.

Highlights from the Presentations

Among the numerous abstracts, notable presentations include results from the Beat AML® Master Clinical Trial, particularly the OPTI-AML study. This randomized phase 2 trial investigates a reduced venetoclax treatment schedule for newly diagnosed patients aged 60 and older with acute myeloid leukemia (AML).

Results indicate a slight reduction in remission rates, with 49% of patients on the standard 28-day regimen achieving complete remission, compared to 43% on the shortened 14-day schedule. While traditional methods offer more robust overall effectiveness, the study raises essential questions about managing treatment-related toxicity, especially in older patients susceptible to serious complications from prolonged low blood counts.

As part of the research, data was derived from a nationwide sample, exploring various aspects of patient care, including factors like Medicaid expansion implications on survival rates and strategies to boost recruitment of adolescents and young adults facing blood cancer. Each abstract at ASCO sheds light on persistent inequities and barriers in accessing cutting-edge therapies.

Looking to the Future

The findings underline the importance of tailoring treatment based on individual patient profiles rather than universally applying a single approach. As new therapies and optimized treatment durations are explored, Blood Cancer United reiterates the urgent need for ongoing research in this dynamic field of medicine.

In a statement, Ashley Yocum, Ph.D., the Executive Research Lead of the Beat AML Master Clinical Trial, emphasized the dedication to gleaning insights that will inform therapeutic advancements and enhance patient experiences. The upcoming discussions at ASCO and EHA aim to foster collaboration within the medical community to address critical gaps in patient care and accessibility.

About Blood Cancer United

Established in 1949, Blood Cancer United (formerly known as The Leukemia & Lymphoma Society) is the premier nonprofit organization dedicated to supporting individuals affected by blood cancer. Through its ongoing commitment to research funding, advocacy, and patient support, Blood Cancer United has become a leader in shaping the future of blood cancer treatment. The organization actively seeks to improve the quality of life for patients and advocates for more comprehensive healthcare access, tirelessly striving for breakthroughs that will benefit patients globally.

For more information, patients and healthcare providers are encouraged to visit BloodCancerUnited.org.